Cargando...
The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
Sarcomas are a diverse set of malignancies. For soft tissue sarcomas, the kinase and chaperone inhibitor pazopanib is a standard of care therapeutic. Previously, we demonstrated that HDAC inhibitors enhanced pazopanib lethality against sarcoma and other tumor cell types in vitro and in vivo. The pre...
Gardado en:
| Publicado en: | Front Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6657367/ https://ncbi.nlm.nih.gov/pubmed/31380285 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00650 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|